Using #MassCytometry, this #STTT study characterized the #ImmuneLandscape of #ESCC, demonstrating that targeting CD39⁺ T cells & PD-L1⁺ macrophages can reprogram the #TumorMicroenvironment to optimize #Immunotherapy response.
#OpenAccess: doi.org/10.1038/s413...
#OpenAccess: doi.org/10.1038/s413...
January 10, 2026 at 6:00 PM
Using #MassCytometry, this #STTT study characterized the #ImmuneLandscape of #ESCC, demonstrating that targeting CD39⁺ T cells & PD-L1⁺ macrophages can reprogram the #TumorMicroenvironment to optimize #Immunotherapy response.
#OpenAccess: doi.org/10.1038/s413...
#OpenAccess: doi.org/10.1038/s413...
Featured today by @MSKLibrary: Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific dx.doi.org/10.1016/j.xc...
#CancerImmunotherapy #TumorMicroenvironment
#ImmunoOncology #TCellTherapy #Tebentafusp #CD3Engager #ImmuneLandscape #Cancer
#CancerImmunotherapy #TumorMicroenvironment
#ImmunoOncology #TCellTherapy #Tebentafusp #CD3Engager #ImmuneLandscape #Cancer
April 23, 2025 at 4:34 PM
Featured today by @MSKLibrary: Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific dx.doi.org/10.1016/j.xc...
#CancerImmunotherapy #TumorMicroenvironment
#ImmunoOncology #TCellTherapy #Tebentafusp #CD3Engager #ImmuneLandscape #Cancer
#CancerImmunotherapy #TumorMicroenvironment
#ImmunoOncology #TCellTherapy #Tebentafusp #CD3Engager #ImmuneLandscape #Cancer